On September 2, 2022, Paul Daruwala notified Cidara Therapeutics, Inc. (the “Company”) of his intent to resign, effective September 30, 2022, from his positions with the Company, including as its Chief Operating Officer and Chief Commercial Officer. Mr. Daruwala is leaving the Company in order to accept a position as Chief Executive Officer of a preclinical-stage private biotechnology company. Effective as of the date of Mr. Daruwala's resignation, Shane M. Ward, Chief Legal Officer of the Company, will be promoted to Chief Operating Officer and Chief Legal Officer.

There will be no change to Mr. Ward's compensation arrangements with the Company at this time.